1. Rodríguez Murúa S, Farez MF, Quintana FJ. The immune response in multiple sclerosis. Annu Rev Pathol. 2022;17:121-39. [
Link] [
DOI:10.1146/annurev-pathol-052920-040318]
2. Soud SA, Al-Rubaei SHN. Study of ABO system and multiple sclerosis disease in Iraq. Iraqi J Sci. 2022;63(6):2345-53. [
Link] [
DOI:10.24996/ijs.2022.63.6.3]
3. Yahya RN, A-Kasim A, Al Gawwam AG. Comparing the quality of life among patients with relapsing remitting multiple sclerosis in Iraq using different disease modifying therapies. Iraq J Pharm Sci. 2018;27(2):102-14. [
Link] [
DOI:10.31351/vol27iss2pp102-114]
4. Lassemi E, Sahraian MA, Motamedi MHK, Valayi N, Moradi N, Lasemi R. Oral and facial manifestations of patients with multiple sclerosis. Dentistry. 2014;4:2-4. [
Link] [
DOI:10.4172/2161-1122.1000194]
5. Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: From the clinical picture to the treatment options. J Headache Pain. 2019;20(1):20. [
Link] [
DOI:10.1186/s10194-019-0969-0]
6. da Cunha ETS, Figueiredo-Godoi LMA, Santos DH, Carneiro RPCD, do Olival GS, de Barros, et al. Oral colonization by candida species in patients with multiple sclerosis. Mycopathologia. 2020;185(6):983-91. [
Link] [
DOI:10.1007/s11046-020-00486-1]
7. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73. [
Link] [
DOI:10.1016/S1474-4422(17)30470-2]
8. Marvin M. Goldenberg multiple sclerosis review. Pharm Ther. 2012;37(3):175-84. [
Link]
9. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-91. [
Link] [
DOI:10.1001/jamaneurol.2019.3365]
10. Loma I, Heyman R. Multiple sclerosis: Pathogenesis and treatment. Curr Neuropharmacol. 2011;9(3):409-16. [
Link] [
DOI:10.2174/157015911796557911]
11. Dhib-Jalbut S, Marks S. Interferon- mechanisms of action in multiple sclerosis. Neurology. 2010;74(1):S17-24. [
Link] [
DOI:10.1212/WNL.0b013e3181c97d99]
12. Zorba M, Melidou A, Patsatsi A, Ioannou E, Kolokotronis A. The possible role of oral microbiome in autoimmunity. Int J Women Dermatol. 2020;6(5):357-64. [
Link] [
DOI:10.1016/j.ijwd.2020.07.011]
13. Zangeneh Z, Abdi-Ali A, Khamooshian K, Alvandi A, Abiri R. Bacterial variation in the oral microbiota in multiple sclerosis patients. PLoS One. 2021;16(11):e0260384. [
Link] [
DOI:10.1371/journal.pone.0260384]
14. Leelapornpisid W, Novak‐Frazer L, Qualtrough A, Rautemaa‐Richardson R. Effectiveness of D,L‐2‐hydroxyisocaproic acid (HICA) and alpha‐mangostin against endodontopathogenic microorganisms in a multispecies bacterial- fungal biofilm in an ex vivo tooth model. Int Endod J. 2021;54(12):2243-55. [
Link] [
DOI:10.1111/iej.13623]
15. Patel M. Oral cavity and candida albicans: Colonisation to the development of infection. Pathogen. 2022;11(3):335. [
Link] [
DOI:10.3390/pathogens11030335]
16. Othman KI, Abdullah SM, Ali B, Majid M. Isolation and identification Candida spp from urine and antifungal susceptibility test. Iraq J Sci. 2018;59(4B):1981-8. [
Link] [
DOI:10.24996/ijs.2018.59.4B.3]
17. Chouhan S, Kallianpur S, Prabhu KT, Tijare M, Kasetty S, Gupta S. Candidal prevalence in diabetics and its species identification. Int J Appl Basic Med Res. 2019;9(1):49-54. [
Link] [
DOI:10.4103/ijabmr.IJABMR_259_18]
18. Junqueira JC, Vilela SFG, Rossoni RD, Barbosa JO, Costa ACBP, Rasteiro VMC, et al. Oral colonization by yeasts in HIV-positive patients in Brazil. Rev Inst Med Trop Sao Paulo. 2012;54(1):17-24 [
Link] [
DOI:10.1590/S0036-46652012000100004]
19. Ibraheem MT, Al-Aswad FD. Oral manifestations, microbial study and salivary iga study in asthmatic patients receiving prednisolone. J Baghdad Coll Dent. 2014;26(2):87-93. [
Link] [
DOI:10.12816/0015201]
20. Pisa D, Alonso R, Carrasco L. Fungal infection in a patient with multiple sclerosis. Eur J Clin Microbiol Infect Dis. 2011;30():1173-80. [
Link] [
DOI:10.1007/s10096-011-1206-1]
21. Benito-León J, Pisa D, Alonso R, Calleja P, Díaz-Sánchez M, Carrasco L. Association between multiple sclerosis and Candida species: Evidence from a case- control study. Eur J Clin Microbiol Infect Dis. 2010;29:1139-45. [
Link] [
DOI:10.1007/s10096-010-0979-y]
22. Purzycki CB, Shain DH. Fungal toxins and multiple sclerosis: A compelling connection. Brain Res Bull. 2010;82(1-2):4-6. [
Link] [
DOI:10.1016/j.brainresbull.2010.02.012]
23. Fraga-Silva TFC, Mimura LAN, Marchetti CM, Chiuso-Minicucci F, França TGD, Zorzella-Pezavento SFG, et al. Experimental autoimmune encephalomyelitis development is aggravated by candida albicans infection. J Immunol Res. 2015;2015:635052. [
Link] [
DOI:10.1155/2015/635052]
24. Winkelmann A, Loebermann M, Reisinger EC, Zettl UK. Multiple sclerosis treatment and infectious issues: Update 2013. Clin Exp Immunol. 2014;175(3):425-38. [
Link] [
DOI:10.1111/cei.12226]
25. Scotto R, Reia A, Buonomo AR, Moccia M, Viceconte G, Pisano E, et al. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: A comprehensive review. Expert Opin Drug Saf. 2021;20(8):925-36. [
Link] [
DOI:10.1080/14740338.2021.1918673]
26. De Pauw A, Dejaeger E, D'hooghe B, Carton H. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg. 2002;104(4):345-51. [
Link] [
DOI:10.1016/S0303-8467(02)00053-7]
27. Poorjavad M, Derakhshandeh F, Etemadifar M, Soleymani B, Minagar A, Maghzi AH. Oropharyngeal dysphagia in multiple sclerosis. Mult Scler. 2010;16(3):362-5. [
Link] [
DOI:10.1177/1352458509358089]
28. Österberg A, Boivie J, Thuomas KÅ. Central pain in multiple sclerosis- Prevalence and clinical characteristics. Eur J Pain. 2005;9(5):531-42. [
Link] [
DOI:10.1016/j.ejpain.2004.11.005]